Innoviva Dirección

Dirección controles de criterios 4/4

El CEO de Innoviva es Pavel Raifeld , nombrado en May 2020, tiene una permanencia de 4.5 años. compensación anual total es $868.65K, compuesta por 55.8% salario y 44.2% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.019% de las acciones de la empresa, por valor de €210.67K. La antigüedad media del equipo directivo y de la junta directiva es de 2.9 años y 6.8 años, respectivamente.

Información clave

Pavel Raifeld

Chief Executive Officer (CEO)

US$868.6k

Compensación total

Porcentaje del salario del CEO	55.8%
Permanencia del CEO	4.5yrs
Participación del CEO	0.02%
Permanencia media de la dirección	2.9yrs
Promedio de permanencia en la Junta Directiva	6.8yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Pavel Raifeld en comparación con los beneficios de Innoviva?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	US$65m
Jun 30 2024	n/a	n/a	US$145m
Mar 31 2024	n/a	n/a	US$181m
Dec 31 2023	US$869k	US$485k	US$180m
Sep 30 2023	n/a	n/a	US$50m
Jun 30 2023	n/a	n/a	US$233m
Mar 31 2023	n/a	n/a	US$233m
Dec 31 2022	US$2m	US$440k	US$214m
Sep 30 2022	n/a	n/a	US$293m
Jun 30 2022	n/a	n/a	US$99m
Mar 31 2022	n/a	n/a	US$188m
Dec 31 2021	US$1m	US$391k	US$266m
Sep 30 2021	n/a	n/a	US$309m
Jun 30 2021	n/a	n/a	US$265m
Mar 31 2021	n/a	n/a	US$253m
Dec 31 2020	US$2m	US$222k	US$224m

Compensación vs. Mercado: La compensación total de Pavel($USD868.65K) está por debajo de la media de empresas de tamaño similar en el mercado German ($USD1.48M).

Compensación vs. Ingresos: La compensación de Pavel ha sido consistente con los resultados de la empresa en el último año.

CEO

Pavel Raifeld (40 yo)

4.5yrs

Permanencia

US$868,648

Compensación

Mr. Pavel Raifeld, CFA, is Director of La Jolla Pharmaceutical Company since August 22, 2022. He serves as Chief Executive Officer of Innoviva, Inc. since May 2020. He is a seasoned healthcare executive wi...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Pavel Raifeld	Chief Executive Officer	4.5yrs	US$868.65k	0.019% € 210.7k
Stephen Basso	Chief Financial Officer	1.3yrs	US$1.18m	sin datos
Marianne Zhen	Chief Accounting Officer & Secretary	6.3yrs	US$924.21k	0.072% € 811.4k
Patricia Drake	Chief Commercial Officer-Innoviva Specialty Therapeutics	less than a year	sin datos	sin datos

2.9yrs

Permanencia media

56.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de HVE se considera experimentado (2.9 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Jules Haimovitz	Independent Director	6.8yrs	US$446.02k	0.19% € 2.1m
Sapna Srivastava	Independent Director	1.8yrs	US$547.11k	0.041% € 459.6k
Derek Small	Independent Director	less than a year	sin datos	sin datos
Odysseas Kostas	Independent Director	6.9yrs	US$331.18k	0.17% € 2.0m
Sarah Schlesinger	Independent Director	6.8yrs	US$367.25k	0.17% € 1.9m
Mark DiPaolo	Independent Director	6.8yrs	US$396.59k	0.17% € 1.9m

6.8yrs

Permanencia media

53yo

Promedio de edad

Junta con experiencia: La junta directiva de HVE se considera experimentada (6.8 años de antigüedad promedio).

Innoviva Dirección

Dirección controles de criterios 4/4

Información clave

Actualizaciones recientes de la dirección

Innoviva, Inc.'s Subsidiary Innoviva Specialty Therapeutics, Inc. Appoints Patricia Drake as Chief Commercial Officer

Innoviva, Inc., Annual General Meeting, Jun 17, 2024

Innoviva, Inc. Appoints David Altarac as Chief Medical Officer of Innoviva Specialty Therapeutics

Chief Accounting Officer & Secretary recently sold €142k worth of stock

Innoviva, Inc. Appoints Stephen Basso as Chief Financial Officer

Innoviva, Inc. Announces Resignation of Deborah L. Birx as Member of the Board of Directors and Chair of the Audit Committee

Recent updates

Third quarter 2024 earnings released: EPS: US$0.019 (vs US$1.26 in 3Q 2023)

New minor risk - Financial position

New minor risk - Profit margin trend

Second quarter 2024 earnings released: US$0.56 loss per share (vs US$0.02 profit in 2Q 2023)

Innoviva, Inc.'s Subsidiary Innoviva Specialty Therapeutics, Inc. Appoints Patricia Drake as Chief Commercial Officer

New minor risk - Financial position

Now 21% undervalued after recent price drop

First quarter 2024 earnings released: EPS: US$0.58 (vs US$0.51 in 1Q 2023)

Innoviva, Inc., Annual General Meeting, Jun 17, 2024

Innoviva, Inc.'s Subsidiary Innoviva Specialty Therapeutics, Inc.’s Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024

Full year 2023 earnings released: EPS: US$2.75 (vs US$3.07 in FY 2022)

Innoviva, Inc. Appoints David Altarac as Chief Medical Officer of Innoviva Specialty Therapeutics

Chief Accounting Officer & Secretary recently sold €142k worth of stock

Third quarter 2023 earnings released: EPS: US$1.26 (vs US$3.81 in 3Q 2022)

Innoviva, Inc. Appoints Stephen Basso as Chief Financial Officer

Innoviva Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with Nasdaq’s Audit Committee Composition Requirements

New major risk - Financial position

Second quarter 2023 earnings released: EPS: US$0.02 (vs US$0.013 in 2Q 2022)

Innoviva, Inc. Announces Resignation of Deborah L. Birx as Member of the Board of Directors and Chair of the Audit Committee

First quarter 2023 earnings released: EPS: US$0.51 (vs US$0.23 in 1Q 2022)

Full year 2022 earnings released: EPS: US$3.07 (vs US$3.24 in FY 2021)

Innoviva, Inc. Announces Appointment of Sapna Srivastava to the Board of Directors

Innoviva, Inc Announces FDA Acceptance and Priority Review of New Drug Application for Sulbactam-Durlobactam

Third quarter 2022 earnings released: EPS: US$3.81 (vs US$1.04 in 3Q 2021)

Innoviva, Inc. (NasdaqGS:INVA) announces an Equity Buyback for $100 million worth of its shares.

Innoviva, Inc. (NasdaqGS:INVA) completed the acquisition of La Jolla Pharmaceutical Company (NasdaqCM:LJPC).

Second quarter 2022 earnings released: EPS: US$0.013 (vs US$1.01 in 2Q 2021)

Royalty Pharma plc (NasdaqGS:RPRX) completed the acquisition of 15% stake in Theravance Respiratory Company, LLC from Innoviva, Inc. (NasdaqGS:INVA).

Innoviva, Inc. (NasdaqGS:INVA) completed the acquisition of the remaining 40% stake in Entasis Therapeutics Holdings Inc. (NasdaqGM:ETTX) from a group of shareholders.

Innoviva, Inc. (NasdaqGS:INVA) completed the acquisition of the remaining 40% stake in Entasis Therapeutics Holdings Inc. (NasdaqGM:ETTX) from a group of shareholders.

First quarter 2022 earnings released: EPS: US$0.23 (vs US$0.93 in 1Q 2021)

Investor sentiment improved over the past week

Innoviva, Inc. (NasdaqGS:INVA) submitted a non-binding proposal to acquire all of the remaining shares of Entasis Therapeutics Holdings Inc. (NasdaqGM:ETTX).

Independent Chairman of the Board recently bought €216k worth of stock

Innoviva, Inc. (NasdaqGS:INVA) announces an Equity Buyback for 32,000,000 shares, representing 32% for $392 million.

First quarter 2021 earnings released: EPS US$0.93 (vs US$0.65 in 1Q 2020)

Innoviva, Inc. Appoints Deborah L. Birx to its Board of Directors

Full year 2020 earnings released: EPS US$2.22 (vs US$1.56 in FY 2019)

Revenue beats expectations

Full year 2020 earnings released: EPS US$2.21 (vs US$1.56 in FY 2019)

Revenue beats expectations

New 90-day high: €10.20

New 90-day high: €10.00

Investor sentiment improved over the past week

Innoviva, Inc. Enters into Strategic Partnership with Sarissa Capital Management LP

Third quarter earnings released

New 90-day low: €8.40

New 90-day low: €9.25

New 90-day low - €10.60

New 90-day low - €11.10

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad